Change search
ReferencesLink to record
Permanent link

Direct link
In vivo monoclonal antibody treatment with Ox19 (anti-rat CD5) causes disease relapse and terminates P2-induced immunospecific tolerance in experimental allergic neuritis.
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Surgery.
Show others and affiliations
1989 (English)In: Journal of Neuroimmunology, ISSN 0165-5728, E-ISSN 1872-8421, Vol. 23, no 1, 11-18 p.Article in journal (Refereed) Published
Abstract [en]

The role of CD5+ lymphocytes in the recovery phase and on immunospecific protection against experimental allergic neuritis (EAN) was examined in Lewis rats by in vivo treatment with Ox19, a mouse anti-rat CD5 monoclonal antibody. Animals pretreated with the peripheral nerve basic protein P2 and thereby rendered resistant to the disease showed clinical signs of EAN after intraperitoneal (i.p.) Ox19 injection given at the same time as the rechallenge with neuritogenic doses of myelin in Freund's complete adjuvant. Non-pretreated rats recovered from signs of EAN developed a clinical relapse after i.p. Ox19 injections. Taken together, these data suggest an important regulatory role of the CD5 receptor in the immune response.

Place, publisher, year, edition, pages
1989. Vol. 23, no 1, 11-18 p.
Keyword [en]
Experimental allergic neuritis, Immunospecific tolerance, CD5, Ox19, Monoclonal antibody therapy, Lewis rat
National Category
Research subject
URN: urn:nbn:se:umu:diva-124043PubMedID: 2470777OAI: diva2:947411
Available from: 2016-07-08 Created: 2016-07-08 Last updated: 2016-07-08

Open Access in DiVA

No full text


Search in DiVA

By author/editor
Strigård, Karin
By organisation
In the same journal
Journal of Neuroimmunology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 2 hits
ReferencesLink to record
Permanent link

Direct link